Arcus Biosciences, Inc. (RCUS) Stock Price & How to Invest

Arcus runs a single reportable segment out of Hayward, California with roughly 600 employees, and it has never generated revenue from product sales. Every dollar recognized since the 2018 IPO has come from research, collaboration and license arrangements, principally with Gilead Sciences and Japan's Taiho Pharmaceutical. Gilead paid $725 million in 2022 to license the anti-TIGIT program (domvanalimab and AB308), the adenosine receptor program (etrumadenant) and the CD73 program (quemliclustat), plus a further $100 million option continuation payment received in 2024. Taiho holds rights across Japan and much of Asia excluding China to five Arcus programs, exercised its casdatifan option in the fourth quarter of 2025 for $15 million, and became obligated in the second quarter of 2026 to pay a $30 million clinical milestone tied to the Phase 3 PEAK-1 study. Those payments sit in deferred revenue and are released to the income statement as Arcus performs the underlying research, so reported revenue tracks the pace of laboratory and trial work rather than any commercial activity. The portfolio itself has narrowed sharply. Gilead returned the etrumadenant license in 2025, three Phase 3 studies of domvanalimab have been stopped since December 2025, and casdatifan, which Arcus owns outright, is what remains.

What the market is paying for sits in one indication. Casdatifan is an oral HIF-2alpha inhibitor for clear cell renal cell carcinoma, a class in which Merck's belzutifan is the only approved drug, and Arcus leads global development while working through regional partners. PEAK-1, a Phase 3 comparing casdatifan plus cabozantinib against cabozantinib alone in patients who have already had immunotherapy, is expected to complete enrollment by the end of 2026, and a second registrational study, PEAK-20, in first-line disease with nivolumab and ipilimumab, is meant to start in the same window. Management has publicly framed the commercial opportunity at $5 billion to $10 billion. The reported numbers move the other way: revenue fell 74% year over year in the second quarter to $41 million, the trailing twelve-month net loss is ~$460 million, and cash plus marketable securities dropped from $1.01 billion at the end of 2025 to $775 million at June 30, 2026. The company guides to roughly $600 million at year-end 2026 and to a runway lasting into at least the second half of 2028, which places its next financing decision after the data that will define the asset.

Concentration is the central risk. Three Phase 3 domvanalimab studies read out badly inside nine months, and Arcus itself warns in the filing that Phase 2 results were not predictive: EDGE-Gastric showed median overall survival beyond two years against Phase 3 benchmarks of 13 to 14 months, yet STAR-221 was still stopped in December 2025 for no benefit over standard of care. The same caution attaches to reading ARC-20 across into PEAK-1 and PEAK-20. Competitively, casdatifan enters a class Merck already occupies with belzutifan, which carries approval, a sales force and years of prescriber familiarity. On the financial side the revenue line is mechanically shrinking: deferred revenue fell to $56 million at June 30, 2026 from $78 million at year end and $319 million two years before, and partnership reimbursements that offset R&D dropped to $36 million for the half from $71 million, so reported expense can worsen even where gross spending falls. The Hercules loan is secured by substantially all of the company's assets and carries a minimum cash covenant beginning in July 2027, conditionally waived only if market capitalization exceeds a specified threshold, tying a financing covenant to the share price at the moment a data disappointment would bite hardest. Gilead's ~24.7% position is registered and no longer accompanied by board seats, removing one reason for it to sit still. The $200 million at-the-market program and the 29.4 million shares issued during 2025 show how this company funds itself. Accumulated deficit reached $1.704 billion at June 30, 2026, the IRS is examining the 2023 tax year, and standard-of-care comparators including cabozantinib, carboplatin and oxaliplatin are flagged in the filing as difficult to source for trials.

12 analysts publish price targets on RCUS, averaging $38.33 against a $30.34 price as of August 2026, or +26.3%. The published targets run from $23.00 to $47.00, a moderate spread, and the ratings split 10 buy, 3 hold, 0 sell. Over the last six months there have been 8 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RCUS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Arcus Biosciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Casdatifan carries the whole valuation. Arcus owns casdatifan outright outside the Taiho Territory and leads its global development. The most optimistic published target, $47.00, assumes this works close to its best case.

The case against. Concentration is the central risk. The most pessimistic target, $23.00, is roughly what RCUS is worth if this bites instead.

Read the full bull and bear case on RCUS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Arcus Biosciences, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$117 million for the twelve months to June 30, 2026, versus $247 million in fiscal 2025 and $258 million in fiscal 2024. All of it is collaboration revenue from Gilead and Taiho; Arcus has never recorded product sales. Second-quarter 2026 revenue was $41 million against $160 million a year earlier, a 74% decline, because the prior-year quarter included $152 million of license and development services revenue recognized in one go.
• 2026 guidance and the deferred revenue behind it: Management guides GAAP revenue of $65 million to $75 million for full-year 2026, which would be roughly a 70% decline from 2025. The deferred revenue balance that feeds the line stood at $56 million at June 30, 2026 ($19 million current and $37 million noncurrent), down from $78 million at December 31, 2025 and $319 million at December 31, 2024. Remaining performance obligations were disclosed at $256 million at the end of 2025.
• Operating expenses: R&D was $113 million in the second quarter of 2026 and $235 million for the half, down from $139 million and $261 million. G&A was $24 million and $53 million against $29 million and $57 million. Full-year 2025 R&D was $523 million and G&A $110 million. Partnership reimbursements offsetting R&D fell to $36 million for the half from $71 million, and late-stage program spend came in at $111 million versus $129 million.
• Earnings and EPS: Net loss of $91 million, or $0.72 per share, in the second quarter of 2026, and $219 million, or $1.74 per share, for the first half on 125.7 million weighted-average shares. The trailing twelve-month loss is ~$460 million, or ~$3.86 per share. Fiscal 2025 produced a $353 million loss and fiscal 2024 a $283 million loss. Accumulated deficit stands at $1.704 billion. No P/E ratio exists and no income tax was recorded, given forecast full-year net operating losses.
• Cash flow and balance sheet: Cash, cash equivalents and marketable securities of $775 million at June 30, 2026, made up of $150 million cash, $552 million current marketable securities and $73 million long term, down from $1.01 billion at December 31, 2025. Operating cash use was $257 million in the first half. Total assets were $924 million, current liabilities $198 million, long-term debt $101 million under the Hercules facility maturing September 2030, and stockholders' equity $464 million. Guidance is ~$600 million of cash at year-end 2026 and runway into at least the second half of 2028.
• Market pricing: The shares changed hands around $30 in late August 2026 against a 52-week range of roughly $9.92 to $31.74, giving a market capitalization near $3.9 billion on 127,333,376 shares outstanding as of July 30, 2026. Enterprise value is approximately $3.2 billion once ~$775 million of cash and ~$101 million of debt are netted. There is no P/E, no EV/EBITDA and no dividend, since the company loses money at the operating line. Gilead's ~24.7% holding means the tradeable float is materially smaller than the headline share count.

Every conventional multiple here is either undefined or misleading. The ~33x trailing sales figure a screener prints rests on a revenue stream management has already guided down to $65 million to $75 million for 2026, with no commercial engine behind it. The ~$3.2 billion enterprise value instead represents a probability-weighted view of casdatifan in clear cell kidney cancer, a market Arcus sizes at $5 billion to $10 billion, discounted for Phase 3 risk and for the cash the company expects to consume between now and the second half of 2028.

Other names that sit close to RCUS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RCUS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RCUS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RCUS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

As of August 2026, RCUS trades as a single-asset kidney-cancer position backed by ~$775 million of cash rather than as a revenue multiple. The collaboration line on the income statement is running off by design, and the October casdatifan data package is what the ~$3.9 billion market value is being set against.

Whether RCUS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RCUS a buy or a sell?, and where the stock could go from here in the RCUS stock forecast.

For income investors, whether RCUS pays a dividend and how the payout looks is covered in does RCUS pay a dividend? And to weigh RCUS against a peer, read the full side-by-side comparisons: RCUS vs BMY and RCUS vs EXEL.